Epithelial membrane protein-2 (EMP2) is a tetraspan protein predicted to regulate placental development. Highly expressed in secretory endometrium and trophectoderm cells, previous studies suggest that it may regulate implantation by orchestrating the surface expression of integrins and other membrane proteins. In order to test the role of EMP2 in pregnancy, mice lacking EMP2 (Emp2 −/− ) were generated. Emp2 −/− females are fertile but have reduced litter sizes when carrying Emp2 −/− but not Emp2 +/− fetuses. Placentas of Emp2 −/− fetuses exhibit dysregulation in pathways related to neoangiogenesis, coagulation, and oxidative stress, and have increased fibrin deposition and altered vasculature. Given that these findings often occur due to placental insufficiency resulting in an oxygen-poor environment, the expression of hypoxia-inducible factor-1 alpha (HIF-1) was examined.
Introduction
Placental development is a complex process that involves successful interplay between the developing fetus and placenta, the uterus, and the maternal immune system. The reciprocal dialogue between maternal and fetal cells regulates cell invasion and tissue remodelling, as well as modulation of immune responses required to prevent rejection. Given the coordinated nature of the process, dysregulated crosstalk between maternal and fetal cells has been implicated in a number of pregnancy disorders resulting in placental insufficiency, such as recurrent miscarriages, intrauterine growth restriction (IUGR), and pre-eclampsia [1, 2] . As pregnancy-related disorders affect up to a third of all human pregnancies [3] , a better understanding of the proteins involved and their ability to regulate maternal-fetal crosstalk is needed. However, significant challenges exist, as while placental-related disorders in pregnancy occur relatively frequently in humans, their incidence is low in other mammalian species, making models for disease scarce [4] .
While a number of pathological processes can be altered, there is mounting evidence that oxidative stressEMP2 and placentation 247 resulting in miscarriage [3] . In pre-eclampsia, inadequate trophoblastic invasion prevents complete transformation of uterine arteries, resulting in inadequate perfusion [3] . This latter process involves the interplay with maternal immune responses as uterine natural killer (uNK) cells help to regulate uterine vascular adaptations [5] [6] [7] . However, little is known regarding how the crosstalk between trophoblastic invasion and uterine natural killer recruitment occurs.
Epithelial membrane protein-2 (EMP2) is a four-transmembrane protein previously identified on both the uterine epithelial cell surface and the trophectoderm cells of the implanting embryo [8] . On the uterine cell surface, EMP2 has been shown to regulate the expression of select integrins such αv and β3, and physiological knockdown of EMP2 impairs successful implantation [9, 10] . While the role of EMP2 in the trophectoderm is unknown, given the similarities between trophoblasts and cancer cells we predict that its role in the placenta may be similar to its role in cancer, where it promotes a pro-invasive phenotype as well as the release of pro-angiogenic factors [11, 12] .
In this study, we show a novel role of EMP2 in placental development. Emp2 −/− females carrying Emp2 −/− fetuses show a significant reduction in litter size, and loss of EMP2 contributed to placental insufficiency, as evidenced by an increase in oxidative stress responses. Within the human, using a combination of human trophoblast-like cell lines and patient-derived samples, we demonstrate that EMP2 regulates neoangiogenesis and invasion, and loss of EMP2 within trophoblasts of the human placenta correlated with IUGR. These results suggest that EMP2 functions to regulate placentation in both humans and mice and that dysregulation of EMP2 may contribute to the development of IUGR.
Materials and methods

Human placental collection and processing
Institutional review board approval was obtained from UCLA for the collection of placental tissue and was in accordance with the Helsinki Declaration of 1975. Collection and processing of the placentas used for this study have been described previously [13] . Placental tissue was obtained from women with normal pregnancies (n = 9) or with late-onset IUGR (n = 14) as defined by newborn weight ≤ tenth percentile for gestational age and a trajectory of fetal growth deceleration in utero, diagnosed by ultrasound in the third trimester of pregnancy.
Generation of EMP2-null mice
All animal procedures complied with NIH/NIEHS animal care guidelines. C57BL/6 mice carrying a conditional knockout allele for the Emp2 gene (floxed exon 3) were generated commercially (Taconic, Hudson, NY, USA) by standard homologous recombination methods using C57BL/6 ES cells. Targeted clones were electroporated with an Flp recombinase-expressing plasmid to remove the neo cassette, and neo-deleted clones were injected into blastocysts derived from albino C57BL/6 mice [B6(Cg)-Tyrc-2 J/J]. Male chimeras were bred with C57BL/6 N Tac females to generate heterozygous offspring. Germline transmission was detected using coat colour and confirmed by tail DNA genotyping. The heterozygous mice were referred to as Emp2 +/f , with 'f' indicating the targeted 'floxed' allele. The primer sequences used for the detection of the floxed allele and to genotype animals are provided in the supplementary material, Table S1 .
All the other protocols used are described in the supplementary material, Supplementary materials and methods. The data presented in this article have been deposited in the NCBI Gene Expression Omnibus and are accessible through GEO Series accession number GSE81940 (https://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=GSE81940).
Results
EMP2 expression in the mouse placenta
Previous data demonstrated the expression of EMP2 within the murine trophectoderm and decidua at E5.5-E6.5 [8] . To fully characterize its expression in the mouse at various time points during placentation, EMP2 expression was determined using placentas from E6.5 to E16.5. EMP2 was detected in the maternal decidua and embryonic trophoblast-derived tissues throughout gestation in wild-type mouse placentas ( Figure 1 ). Immediately after implantation at E6.5, as previously reported [8] , EMP2 was expressed in the embryo proper, trophoblastic stem cells in the ectoplacental cone, and decidual cells. In E9.5 placentas, EMP2 was strongly expressed in trophoblast giant cells and maternal decidua but was also detectable in the endometrium. No EMP2 expression was detected within the allantois. During murine placental development, four distinct trophoblast populations emerge: labyrinthine trophoblasts, glycogen trophoblasts, spongiotrophoblasts, and trophoblast giant cells [14] . By E12.5, EMP2 was most highly expressed in giant cells but was also found to be weakly expressed within labyrinthine trophoblasts and spongiotrophoblasts found in the junctional zone. At E12.5, pre-glycogen cells appear [15] , and EMP2 appears to reside in a perinuclear/cytoplasmic pattern within these cells. As placentas neared term, EMP2 expression appeared to be greatly reduced in all trophoblast populations.
Generation and fertility phenotype of EMP2-deficient mice using C57BL/6 embryonic stem (ES) cells. Exon 3 of Emp2 was chosen for deletion because it encodes the majority of the first transmembrane domain and its deletion results in a frame-shift mutation in the subsequent exons. The targeting construct contained loxP sites bracketing exon 3 and Flp recombinase sites bracketing the neomycin cassette (supplementary material, Figure S1A ). Correct homologous recombination in the ES cells was demonstrated by southern blotting ( Figure 2A ). The neomycin cassette was deleted in vitro and chimeric founders were generated. Germline transmission of the conditional knockout allele from chimeric founders was documented ( Figure 2B ). Deletion of Emp2 exon 3 in oocytes was accomplished using the oocyte-specific ZP3-cre transgene, which resulted in Emp2 f/− offspring that were crossed to generate Emp2 −/− mice. Because EMP2 is highly expressed in the lung, this tissue was used to examine EMP2 protein EMP2 and placentation 249 production. Immunoblots of lung extracts demonstrated that EMP2 was reduced by about 50% in Emp2 f/− mice and was not detected at all in Emp2 −/− mice ( Figure 2C ). Similarly, EMP2 was not detected in uterine tissue from Emp2 −/− mice (supplementary material, Figure S1B ).
Crosses of Emp2
+/− mice had an average litter size of 7.3 ± 0.51 SEM (N = 19 litters) and resulted in weaned offspring whose genotypes were not different from the expected Mendelian ratio (30% wild-type:51% heterozygous:19% knockout; p = 0.52, chi-square analysis). Based on our previous findings suggesting that physiological knockdown of EMP2 in the mouse uterus was associated with reduced implantation efficiency [8] , we hypothesized that Emp2 −/− females would have fertility defects. Because EMP2 is expressed in the endometrial epithelium, decidual tissue, and the trophoblast layer of the embryo, the embryo genotype was an important factor to consider in the experimental design used to test fertility. Breeding pairs were set up such that all embryos in each litter had the same genotype, while the maternal and paternal genotypes were homozygous wild-type or knockout, and the average litter size was determined for three litters for each genotype combination ( Figure 2D ). There was no reduction in the fecundity of Emp2 −/− females compared with Emp2 +/+ females when the embryos carried were heterozygous (Emp2 +/− ). However, there was a significant reduction in the litter size when the embryos carried were EMP2-deficient (Emp2 −/− ), suggesting that in the context of genetic knockout of EMP2, fetal EMP2 has an important role in regulating placentation. It was not feasible to confirm this finding in heterozygous crosses (Emp2 +/− × Emp2 +/− ) because if we assumed that a similar number of knockout pups would fail to implant, as was observed in litters from Emp2 −/− females (1.2 out of 7.5), and that knockout pups would comprise 25% of each litter findings, it would take extremely large litter numbers to reach either positive or negative significance. Furthermore, it was possible that knockout fetal placentas could secrete factors that could impact the function of heterozygous or wild-type placentas, or vice versa.
To test whether an embryo expressing EMP2 could somehow cause expression of EMP2 in the EMP2-deficient dams, Emp2 −/− females were bred with wild-type (Emp2 +/+ ) males and the implantation sites were examined. At E9.5, EMP2 was detected within the placental giant cells, but not in the maternal endometrium (supplementary material, Figure S2A ). Together with the breeding data, these findings indicate that EMP2 is not required in maternal tissues for successful pregnancy.
Additional breeding studies were performed to compare outcomes in knockout pairs relative to wild-type pairs. Three breeding pairs in each group were mated continuously for 6 months. While there was no difference in pup weight (supplementary material, Figure  S2C ) or length of gestation, knockout pairs were slower to achieve pregnancy over time ( Figure 2D ). Combined with the smaller litter size, this resulted in a lower cumulative number of pups during the breeding trial.
Transcriptome profiling of EMP2-deficient placentas
In order to understand the physiological cellular responses that may be associated with altered EMP2 levels, gene expression analysis was performed. RNA from individual E16.5 placentas was collected and subjected to RNA sequencing. For this and all subsequent experiments, pregnancies were generated from either homozygous knockout (Emp2 −/− × Emp2 −/− ) or wild-type (Emp2 +/+ × Emp2 +/+ ) breeding pairs. Overall, 348 genes showed differential gene expression in Emp2 −/− compared with wild-type placentas based on |log 2 (fold)| > 0.8, false discovery rate < 5% ( Figure 2E ). Whole-genome expression estimates and the list of differentially expressed genes are provided in the supplementary material, Table S2 . To obtain further insight into the mechanisms of EMP2 within the placenta, gene set enrichment analysis (GSEA) was performed using data from a public repository, NCBI GEO ( Figure 2E ). Emp2 −/− placentas showed significant alterations in genes implicated in placental insufficiency and placental deterioration. Indicative of the ischaemic-reperfusion episodes that are predicted to occur during oxidative stress in the placenta [3] , several gene sets were significantly enriched in the knockout placentas related to collagens, angiogenesis, and coagulation. Among these pathways, extracellular matrix Col13a1 and Col27a1 transcripts as well as factors related to coagulation such as the fibrinogen alpha chain and plasminogen were up-regulated in the Emp2 −/− placentas. In contrast, several transcripts related to oxidative phosphorylation were down-regulated in the Emp2 −/− placentas, including components of the NADH oxidase and cytochrome c complex as well as ATP synthase. A summary of the relevant pathways provided by GSEA is given in the supplementary material, Table  S3 . The complete list of genes analysed with regard to coagulation is provided in the supplementary material, Table S4 .
Histological alterations in EMP2-deficient placentas
Transcriptional analysis suggested that the EMP2 knockout placentas may display histological changes, so we next examined the effects of EMP2 deficiency on the organization of the mouse chorioallantoic placenta. Although placentas from wild-type or Emp2 −/− crosses producing corresponding wild-type and Emp2 −/− fetuses showed similar overall architecture (supplementary material, Figure S2B ), careful examination of the extracellular matrix composition showed striking differences. Consistent with the transcriptional differences, collagen deposition appeared to be up-regulated in Emp2 −/− placentas ( Figure 3A ). Masson's trichrome staining revealed characteristic collagen around the yolk sac in both groups, but only the Emp2 −/− placentas displayed collagen throughout the labyrinth at E16.5.
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Coupled with the change in collagen, GSEA analysis suggested that Emp2 −/− placentas increased expression of factors involved with coagulation. In diseases associated with placental insufficiency such as pre-eclampsia, it has been postulated that systemic endothelial damage causes the coagulation cascade to become activated, resulting in excess thromboses in the placenta and renal system [20] . In order to identify microscopic sites of epithelial injury in placental villi, fibrin deposition in E16.5 placentas was measured [21] [22] [23] . PTAH staining showed a striking increase in fibrin deposition throughout the decidua basalis and junctional zones in EMP2-deficient placentas compared with controls ( Figure 3B ).
In humans, abundant fibrin deposition within the placenta is characteristic of the injuries often occurring due to dysregulated villous vasculogenesis [24] . Next, to determine if vasculogenesis was altered between the groups, placentas were stained using a fluorescein-labelled Lycopersicon esculentum lectin. The intensity of lectin staining was reduced by ∼3-fold within the trophoblast-decidua interface in the E9.5 EMP2-deficient placentas ( Figure 3C ). At E12.5, although no quantitative differences in vascular staining intensity were measured, differences in vessel organization were prominent ( Figure 3D ). To confirm the changes in vasculature observed at E9.5, placentas were stained for CD34 to label vascular endothelial cells. CD34 staining was significantly reduced in EMP2-deficient compared with wild-type placentas ( Figure 3E ).
HIF-1α expression and uNK cells are increased in Emp2
−/− mice
The imbalance of vasculogenesis in the EMP2-deficient placentas and the enrichment in genes related to the hypoxic response determined by the GSEA analysis suggested that there may be an imbalance in placental oxygen tension. Within the utero-placental environment, hypoxia-inducible factors (HIFs) mediate transcriptional responses to localized hypoxia by altering cellular metabolism and stimulating angiogenesis [25, 26] , and in particular, HIF-1α levels have been linked with placental disease and impaired trophoblast differentiation [27] [28] [29] . Within both individual and total implantation sites per dam, Hif1α expression was significantly up-regulated in Emp2 −/− compared with Emp2 +/+ ( Figure 4A ). To confirm the up-regulation of the Hif1α transcript, immunohistochemistry was performed to assess protein levels. Although there appeared to be a slight decrease in cytoplasmic HIF-1α in trophoblasts in Emp2 −/− placentas, strikingly, there was a net increase in HIF-1α staining within decidual leukocytes ( Figure 4B ). The effect was pervasive throughout all the implantation sites in a given dam, with more HIF-1α-positive leukocytes at E9.5 and E12.5 present in the Emp2 −/− placentas. The difference in HIF-1α expression was largely abrogated by E16.5, with minimal expression detected in both groups.
To confirm the identification of leukocytes within the placenta, sections of E12.5 placentas were stained using a periodic acid-Schiff stain to detect the distinct appearance of cell granules characteristic of uterine NK (uNK) cells. An increase in granulated leukocytes was confirmed ( Figure 4C and supplementary material, Figure  S3 ). Approximately 70% of the total leukocytes in the mid-gestational decidua are uNK cells, and these cells are thought to organize the maternal-fetal interface and regulate oxygen delivery within the trophoblast stem cell niche [30] [31] [32] . To investigate the numbers of uNK cells, a Dolichos biflorus agglutinin (DBA) lectin stain was performed on placentas from E9.5, E12.5, and E16.5 ( Figure 4D ) [33] . uNK cells were significantly increased in the decidua basalis of EMP2-deficient placentas compared with controls throughout gestation ( Figure 4E) , suggesting that uNK cells may be recruited to help regulate the hypoxic response.
EMP2 is expressed in human placentas and reduced in IUGR pregnancies
Our results thus far suggested that EMP2 may regulate immune cell recruitment and vascularization in the placenta. To determine if the above findings were relevant to human pregnancy, the distribution of EMP2 was initially evaluated in human placental tissue by immunohistochemistry. As in the mouse, all populations of human trophoblasts showed some expression of EMP2. In normal, term placentas, a strong EMP2 signal was present in both villous syncytiotrophobasts and cytotrophoblasts, as well as on the membrane of interstitial trophoblasts ( Figure 5A ).
Pre-eclampsia and late-onset IUGR are uteroplacental disorders resulting from inadequate trophoblast invasion and a failure to properly remodel the maternal blood supply, resulting in overall placental insufficiency [34] . In placentas from pregnancies complicated by late-onset IUGR, EMP2 protein was reduced ∼2-fold, as indicated by immunoblot analysis ( Figure 5B) , with the alteration in expression present on both the fetal and the maternal sides of the placenta. To confirm these results, semi-quantitative immunohistochemical analysis of placentas from normal and late-onset IUGR was performed, and both placental villi and interstitial trophoblast cells showed lower EMP2 expression in placentas complicated by IUGR compared with controls ( Figure 5C ).
EMP2 promotes angiogenesis in human trophoblastic cells
Each population of trophoblast cells in the human has distinct functions. Extravillous trophoblasts mediate invasion into the maternal decidua, while cytotrophoblasts fuse to form syncytiotrophoblasts that regulate passive diffusion between the mother and the fetus as well as select hormonal function [35] . To investigate the functional role of EMP2, its expression was first determined in two cell lines of trophoblast origin, the choriocarcinoma cell lines JAR and BeWo. Both cell lines showed endogenous EMP2 protein expression and were thus engineered to overexpress or reduce EMP2 levels ( Figure 6A ). To determine if EMP2 levels could alter trophoblast differentiation, BeWo cells were used as these cells have been shown to differentiate into syncytiotrophoblasts upon forskolin treatment [36] . No change in beta human chorionic gonadotropin (hCG) production was observed, suggesting that EMP2 is not necessary for differentiation (supplementary material, Figure S4A ).
To next determine if EMP2 levels affect trophoblast migration, a Boyden chamber migration assay was performed. In both JAR and BeWo cells, up-regulation of EMP2 correlated with increased cell migration, while down-regulation in EMP2 inhibited it ( Figure 6B) . Previous studies have shown that trophoblast invasion regulates endothelial cell migration and vascularization [37, 38] . To determine if trophoblasts with altered EMP2 levels modulate capillary vasculogenesis and neoangiogenesis, HUVEC tube formation assays were performed. Supernatants from JAR or BeWo cells with modified EMP2 protein levels dramatically increased capillary tube formation, whereas knockdown of EMP2 did the opposite ( Figure 6C ). While the chemotactic responses of HUVECs to supernatants from EMP2-up-regulated JAR cells showed significantly enhanced directional migration compared with medium from control cells (Figure 6D ), there was a non-significant reduction in directional migration when medium from JAR cells with reduced levels of EMP2 was tested. These data suggested a role for EMP2 in invasion and endothelial cell reorganization, similar to what was observed in the Emp2 −/− placentas. To test whether alterations in HIF-1α levels contributed to these responses, its expression was determined in these modified human trophoblast cell lines. Under normoxic conditions, JAR cells overexpressing EMP2 showed increased HIF-1α, whereas a reduction in EMP2 decreased HIF-1α levels by ∼50% ( Figure 6E) . Next, to determine whether hypoxia could induce a reciprocal increase in EMP2 levels, JAR cells were placed under hypoxic (0.5%) or normoxic (20%) oxygen conditions for 24 h. No differences in total EMP2 protein were observed (supplementary material, Figure S4B ). To determine if HIF-1α controls neoangiogenesis in EMP2 up-regulated cells, JAR/EMP2 and BeWo/EMP2 cells were treated with HIF-1α or scrambled siRNA. Reduction in HIF-1α levels abrogated capillary tube formation in both cell lines ( Figure 6F ), further supporting the idea that EMP2 regulates trophoblast-mediated angiogenesis at least in part by altering HIF-1α levels.
Discussion
The results of the present study define an important regulatory relationship between angiogenesis and uNK regulation at the maternal-fetal interface via the tetraspan protein EMP2. Deletion of EMP2 in fetuses reduced litter sizes (and therefore overall litter weight) by 16%, and placentas from these animals showed signs of oxidative stress and poor vascularization, phenocopying the reproductive outcomes and histological changes seen in human placental insufficiency. In an effort to translate these findings, we provide the first evidence of altered EMP2 expression in human placentas with IUGR. A significant reduction in EMP2 levels was observed in both villous and extravillous trophoblasts, and coupled with results from Emp2 −/− animals, these findings suggest that it has a protective role in pregnancy establishment.
The crosstalk between maternal decidual cells, extravillous trophoblasts, and uNK cells sets into motion a number of events including the plugging and remodelling of maternal vessels and regulation of the oxygen level [5] [6] [7] . In the human, trophoblasts differentiate along two pathways to give rise to either extravillous or villous trophoblasts that resemble giant cells or labyrinthine trophoblasts in the mouse, respectively. Within these cells, EMP2 appears to regulate a number of functions including invasion and vasculogenesis, as well as playing a role in regulating the hypoxic response. Under normal conditions, the placenta adapts to changing oxygen levels to support normal placental function and fetal development by modulation of HIF-1α [39] . In humans, first-trimester chorionic villi show detectable HIF-1α levels [40] , while in mice, HIF-1α has been observed in several trophoblast populations including giant cells and cytotrophoblasts [25, 41, 42] . This is similar to the results presented here, as wild-type human and murine trophoblasts express HIF-1α, and our results suggest that under normal, physiological conditions, this regulation occurs at least in part through EMP2. Based on our findings in this genetic knockout model, we cannot speculate as to whether hypoxia itself leads to altered localization of EMP2 protein in vivo, but our in vitro studies suggest that hypoxia does not modulate total EMP2 levels (supplementary material, Figure  S1 ). Taken together with the hypovascularity seen in EMP2 knockout, our findings indicate that EMP2 is upstream of HIF-1α and that lack of its expression leads to placental hypoxia because of a failure of appropriate placental angiogenesis. Curiously, the expression of HIF-1α in wild-type murine trophoblasts appears more cytoplasmic than nuclear. This may reflect a known dynamic whereby HIF-1α shuttles between the cytoplasm and the nucleus or it may reflect an alteration in HIF-1α protein turnover [43] [44] [45] . While this study did not address the mechanism behind EMP2 regulation of HIF-1α, previous studies using normal and cancer cell lines suggest that EMP2 expression promotes FAK and Src activation [11, 46] . Both of these pathways regulate HIF-1α [47] but additional studies will be needed to determine the downstream pathway governing EMP2-mediated HIF-1α expression within trophoblasts.
Moreover, our results show that the Emp2 −/− placenta increased the recruitment and retention of uNK cells throughout gestation. uNK cells are distinct phenotypically from peripheral blood NK cells, exhibiting low cytotoxicity and high cytokine-secreting activity [42, 48] . Over the last decade, it has been proposed that EMP2 and placentation 257 uNK cells cooperate with trophoblast cells to guarantee correct arterial remodelling [49] , and we thus predict that these cells may be providing a compensatory mechanism for inadequate trophoblast-mediated vascular remodelling due to loss of EMP2 in the knockout animals. In support of this hypothesis, Emp2 −/− placentas had a significant increase in recruitment and subsequent expression of HIF-1α in uNK cells.
An intriguing aspect to this work is the suggestion that EMP2 may play a part in the development of placental insufficiency-related pregnancy disorders such as pre-eclampsia and IUGR. Importantly, it appears that in this genetic knockout of EMP2, implantation per se is not significantly affected but that placental vascularization and maintenance are affected. Previous studies have shown that the progressive deterioration in placental function typically manifests in hypoxaemia and oxidative stress as the placenta cannot provide sufficiently for the metabolic demands of the growing fetus [50, 51] . While a number of signalling pathways likely contribute, it has been argued that the most important ones for pregnancy are perturbations in the maternal blood supply to the placenta and excessive inflammation [3, 52] . Consistent with this description, placentas from the Emp2 −/− fetuses show reduced angiogenesis, as documented by the differences in CD34 and lectin staining. Moreover, placental damage was evident from the gene set enrichment signature and confirmed by the increase in fibrin and collagen deposition near the maternal-fetal interface. The lack of growth restriction (e.g. birth weight; supplementary material, Figure  S1C ) observed in the Emp2 −/− offspring is not surprising given that, in contrast to humans, trophoblast invasion of the endometrium remains superficial [53] .
The altered placental vascularization seen in pregnancy-related disorders such as growth restriction and pre-eclampsia is incompletely understood. Determining the mechanisms by which placental vascularization occurs will be important in identifying markers for high-risk pregnancies, for targeting therapies in these pregnancies, and also to better elucidate fetal effects in the short term as well as in later disease. Although we predict that altered EMP2 may be a link for the development of placental insufficiency, additional experiments will be necessary to determine its penetrance. Table S1 . Primer sequences used for the detection of the floxed allele and to genotype animals Table S2 . Whole-genome expression estimates and the list of differentially expressed genes between placentas isolated from wild-type and EMP2-null mice Table S3 . Summary of the relevant pathways altered in EMP2-null placentas provided by GSEA Table S4 . Differential expression of genes in wild-type versus EMP2-null placenta analysed with regard to coagulation
SUPPLEMENTARY MATERIAL ONLINE
